01:19 , Feb 16, 2018 |  BC Innovations  |  Product R&D

Banking on the placenta

Celgene Corp. spinout Celularity Inc. is aiming to disrupt the stem cell market with a platform of placenta-based cell therapies whose intrinsic allo-tolerance could provide a broadly applicable system for propelling off-the-shelf cancer therapies into...
15:18 , Sep 1, 2017 |  BC Week In Review  |  Financial News

Celularity launches with undisclosed series A

Celularity Inc. (Warren, N.J.) launched on Aug. 21 with an undisclosed series A round, as well as assets and IP, from Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp. (NASDAQ:UTHR), Human Longevity Inc. (San Diego, Calif.)...
23:56 , Aug 21, 2017 |  BC Extra  |  Financial News

Celularity debuts to develop placenta-based cell therapies

Celularity Inc. (Warren, N.J.) launched with an undisclosed series A round, as well as assets and IP, from Sorrento Therapeutics Inc. (NASDAQ:SRNE), United Therapeutics Corp. (NASDAQ:UTHR), Human Longevity Inc. (San Diego, Calif.) and additional undisclosed...
23:20 , Apr 7, 2017 |  BioCentury  |  Finance

Taking notice

  Political overhang during the first quarter kept generalists on the sidelines but provided a buying opportunity for life sciences specialists that led the sector to outperform. With “repeal and replace” in the rearview for now...
05:18 , Mar 31, 2017 |  BC Week In Review  |  Financial News

Alliqua BioMedical completes follow-on

On March 29, regenerative medicine company Alliqua BioMedical Inc. (NASDAQ:ALQA) raised $3.8 million through the sale of 9.5 million shares at $0.40 in a follow-on underwritten by H.C. Wainwright. Alliqua BioMedical Inc. (NASDAQ:ALQA), Yardley, Pa.  ...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Financial News

Alliqua BioMedical financial update

Alliqua BioMedical Inc. (NASDAQ:ALQA), Langhorne, Pa.   Business: Drug delivery, Hepatic, Dermatology   Date announced: 2014-08-05   Note: Alliqua filed a shelf registration covering the sale of up to $100 million of its securities. The company, which closed...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Alliqua, Choice Therapeutics deal

Alliqua acquired fellow wound care company Choice in a cash and stock deal that values Choice at $4 million. Choice shareholders are also eligible for up to $5 million in stock or cash if revenue...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Company News

ContraVir Pharmaceuticals management update

ContraVir Pharmaceuticals Inc. (OTCBB:CTRV), New York, N.Y.   Business: Infectious   Hired: James Sapirstein as CEO and a director, formerly CEO of Alliqua Therapeutics at Alliqua Inc.   ...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Company News

Alliqua management update

Alliqua Inc. (OTCBB:ALQAD), Langhorne, Pa.   Business: Drug delivery, Hepatic, Dermatology   Hired: Janice Smiell as CMO, a newly created position, formerly an independent consultant   ...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Financial News

Alliqua completes private placement of common stock and warrants

Alliqua Inc. (OTCBB:ALQAD), Langhorne, Pa.   Business: Drug delivery, Hepatic, Dermatology   Date completed: 11/19/13   Type: Private placement of common stock and warrants   Raised: $7 million   Shares: 2 million   Price: $3.59   Shares after offering: 10.7 million   Placement...